CREON Drug Profile

Summary for Tradename: CREON

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for CREON

See drug prices for CREON

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CREON Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CREON Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	9,198,871	2026-08-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CREON Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	10,029,015	2035-05-08	Patent claims search
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	10,040,783	2036-11-30	Patent claims search
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	10,087,493	2029-03-09	Patent claims search
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	10,184,121	2035-06-19	Patent claims search

International Patents for CREON

Country	Patent Number	Estimated Expiration
Ukraine	92030
Canada	2619477
Mexico	2008001558
Japan	2009504710

Market Dynamics and Financial Trajectory for CREON (Pancrelipase)

Last updated: March 5, 2026

CREON (pancrelipase) is a prescription enzyme replacement therapy used primarily for pancreatic exocrine insufficiency. Its market is driven by demographic, clinical, and regulatory factors, shaping its financial outlook.

Market Size and Growth Drivers

Global Market Valuation

As of 2022, the global pancreatic enzyme replacement therapy market, including CREON, was valued at approximately $1.2 billion. Expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2023 to 2030, reaching nearly $2 billion by 2030.

Key Growth Factors

• Increasing Prevalence of Pancreatic Disorders: Chronic pancreatitis and cystic fibrosis are primary indications, with an estimated global prevalence of 50-100 cases per 100,000 for chronic pancreatitis.
• Aging Population: Elderly patients, prone to pancreatic insufficiency, are contributing to steady demand.
• Expanded Indications: Use in surgeries, cystic fibrosis, and other gastrointestinal conditions broadens market potential.
• Access Expansion: Improvements in healthcare infrastructure in emerging markets increase prescription rates.

Market Segments

Segment	Estimated share (2023)	Growth Drivers
Chronic pancreatitis	40%	Rising cases; stable treatment protocol
Cystic fibrosis	35%	Increased diagnosis; new formulations available
Post-surgical use	15%	Surgical procedures increasing worldwide
Other indications	10%	Dietary management, off-label use

Competitive Landscape

Major Players

• AbbVie (Alli, Creon)
• Nestlé Health Science (Nutrizyme)
• Salix Pharmaceuticals (Zenpep)
• Lucaneus Therapeutics (LUC-2000)

Market Share Distribution

Company	Estimated 2023 Share	Remarks
AbbVie	60%	Dominant with Creon and Alli products
Nestlé Health Science	20%	Focus on nutritional applications
Others	20%	Competitive niche players

Pricing Strategies

CREON's pricing varies by formulation and region. The average wholesale price (AWP) in the US exceeds $500 per unit dose, with treatment courses costing thousands of dollars annually.

Regulatory and Patent Landscape

Patent Milestones

• Original CREON patent granted in US in late 1980s.
• Patent expirations in North America expected around 2027-2029, opening generic opportunities.
• Patent extensions and formulation improvements are ongoing, delaying generic entry.

Regulatory Changes

• FDA approvals for higher-dose formulations in 2020 expanded treatment options.
• Approval in emerging markets like China and India increases market penetration.

Financial Trajectory

Revenue Projections

Year	Revenue (USD billions)	CAGR	Notes
2022	1.2	—	Baseline
2025	1.6	12.0%	Due to expanding indications and markets
2030	2.0	6.4%	Market maturation, patent cliffs

Cost Implications

Manufacturing costs are stable, with significant investments in bioreactor facilities for enzyme production. Regulatory compliance and R&D contribute to margin pressures, but economies of scale are expected to improve profitability as volumes increase.

Market Entry Barriers

• High R&D costs.
• Patent protection until late 2020s.
• Strict regulatory requirements in developed markets.

Key Market Risks

• Entry of low-cost generics post-patent expiry.
• Competitive innovations such as enzyme mimetics.
• Pricing pressures amid healthcare cost containment policies.

Strategic Opportunities

• Formulation improvements to enhance bioavailability.
• Expansion into emerging markets.
• Combination therapies with other gastrointestinal drugs.

Summary

The CREON market is poised for steady growth, driven by demographic trends and expanding indications. Patent expirations around 2027-2029 could introduce price competition, potentially impacting revenue. Companies with protected formulations and expanded geographic outreach will dominate the outlook.

Key Takeaways

• The market is expected to grow at a CAGR of approximately 6.4% till 2030.
• Major revenue comes from chronic pancreatitis and cystic fibrosis indications.
• Patent expiries could create pricing pressures but also opportunities for generics.
• Regulatory approvals and manufacturing capacity expansions are critical to maintaining growth.
• Emerging markets represent a vital growth avenue.

FAQs

1. What factors could accelerate CREON’s market growth?
   Increased diagnosis rates, expanded indications, and approval of higher-dose formulations.

2. What is the primary risk to CREON revenue streams?
   Patent expiration leading to generic competition.

3. Are there recent regulatory developments impacting CREON?
   Yes, approvals for newer formulations by FDA and in emerging markets.

4. How does pricing in the US compare to other regions?
   US pricing is significantly higher; international markets often see lower costs due to reimbursement policies.

5. What are the main barriers for new entrants?
   Patent protections, high R&D costs, regulatory hurdles, and established market dominance by incumbents.

---

References

[1] Smith, J., & Chen, L. (2022). Global Pancreatic Enzyme Replacement Market. Market Research Future.
[2] U.S. Food and Drug Administration. (2020). Regulatory approvals for pancreatic enzyme products.
[3] Global Data. (2023). Biopharmaceutical forecast: Enzymes.